|Day Low/High||298.70 / 303.51|
|52 Wk Low/High||271.37 / 442.00|
RMPIA is up 20.9% in the first nine months of 2019.
Pfizer shares edged higher Friday after the company posted promising results from trials of a drug it's developing to treat patients with moderate-to-severe eczema.
The company's treatment for nasal polyps receives positive feedback from the European Medicines Agency's Committee for Medicinal Products for Human Use.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
Shares of Gilead Sciences are jumping higher on its increased investment in Galapagos and a new outperform rating from Wells Fargo.
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
* First biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP)
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.